Synthetic tuftsin-derived neuroactive heptapeptide
Selank is a seven-amino-acid tuftsin-derived peptide researched mainly for anxiety, stress, cognition, and immune signaling. Small human studies report anxiety-related signals, but there is no modern large placebo-controlled program establishing efficacy or long-term safety.
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Research at a glance
Depth and confidence summarize the research record—not effectiveness, safety, or a recommendation.
Older anxiety comparator and add-on studies, acute imaging, and biomarker research exist, but no large modern placebo-controlled program was located.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
The human studies are short, small, incompletely masked, and not independently replicated, while mechanism claims remain mostly preclinical.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not a suggested amount.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The studies used different comparators, co-treatments, endpoints, and reporting standards. They do not establish a universal amount, durable benefit, product equivalence, or long-term safety. Amounts shown describe cited research exposure—not a dosage recommendation.
Practical starting point
Common goals and questions—not recommendations or promises of benefit.
The overview, studies, and source ledger below explain what supports each label—and where the evidence stops.
The short version
Selank is a seven-amino-acid tuftsin-derived peptide researched mainly for anxiety, stress, cognition, and immune signaling. Small human studies report anxiety-related signals, but there is no modern large placebo-controlled program establishing efficacy or long-term safety.
Evidence reviewed through July 25, 2026. Small anxiety studies, acute human imaging, biomarker findings, animal mechanisms, and FDA compounding-risk material are labeled separately.
What the evidence says
A 62-person randomized active-comparator study reported anxiety improvement similar to medazepam, while a separate 60-person comparison and 70-person add-on study reported related signals. The studies were small, short, and not independently replicated in a modern placebo-controlled program.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Whether Selank provides reproducible clinical anxiety benefit and what formulation-specific pharmacokinetics, dose-response, interactions, dependence or withdrawal profile, immunogenicity, rare harms, and long-term repeated-use safety look like.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
The evidence story
Importance shows how much an item changes the evidence story. Quality shows how much confidence the design deserves. A strong negative study can score highly on both.
Importance and quality answer different questions. A rigorous study can be highly important even when it challenges a popular claim.
The study reported acute group and time differences involving right-amygdala connectivity with right temporal and parahippocampal regions.
Selank and diazepam produced context-dependent behavioral effects, while the combination most fully reduced the stress-associated anxiety measure in this rat model.
Selank altered many neurotransmission-related transcripts, with partial overlap between Selank- and GABA-associated expression patterns.
The authors reported greater or faster therapeutic effects and fewer phenazepam-related complaints when Selank was added.
The authors reported anxiety improvement, mild nootropic effects, and persistence of the anxiolytic effect for one week after Selank.
Administration and handling
Located clinical reports generally describe intranasal Selank in short research courses. They do not establish a universal dose, route, cycle, combination, or personal-use protocol. No FDA-approved Selank regimen exists, and intranasal findings cannot be transferred to subcutaneous products, modified analogues, or products with unverified identity.
There is no FDA-approved U.S. Selank label, consumer reconstitution method, or official storage instruction. Selank free base, Selank acetate, and chemically modified products should not be assumed interchangeable. FDA highlights aggregation, peptide-related impurities, API-characterization, and immunogenicity concerns for compounded Selank acetate. Vendor handling statements are not regulator-approved stability data.
Primary-source ledger
2026-05-14
2020-04-01
2020-01-01 · PMID 32342318 · DOI 10.1134/S001249662001007X
2017-01-01 · PMID 28280289 · DOI 10.1155/2017/5091027
2016-02-01 · PMID 26924987 · DOI 10.3389/fphar.2016.00031
2015-01-01 · PMID 26356395 · DOI 10.17116/jnevro20151156133-40
2014-01-01 · PMID 25176261
2008-01-01 · PMID 18454096
2008-01-01 · PMID 18577961
2008-01-01 · PMID 18841804
2001-01-01 · PMID 11550013